Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2016
Price : $35 *
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Biotech (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept
- Acronyms CURE-iv
- Sponsors Kangstem Holdings
- 20 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 17 Mar 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History